Evidence map›Paper›PMID 35144620›Full record

Trial reportRespiratory research2022

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.

Dave Singh, Jim M Wild, Dinesh Saralaya, Rod Lawson, Helen Marshall, Jonathan Goldin, Matthew S Brown, Konstantinos Kostikas, Kristin Belmore, Robert Fogel and 6 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Lung functional imaging.Breathe (Sheffield, England) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 5 countries.

Dave SinghMedicines Evaluation Unit, University of Manchester, Manchester University National Health Service Foundation Trust, Manchester, UK.
Jim M WildImaging Sciences, Department of Infection, Immunity and Cardiovascular Disease, POLARIS, University of Sheffield, Sheffield, UK.
Dinesh SaralayaRespiratory Clinical Trials Unit, Bradford Teaching Hospitals National Health Service Foundation Trust, Bradford, UK.
Rod LawsonNational Institute for Health Research, Sheffield Clinical Research Facility, Sheffield, UK.
Helen MarshallImaging Sciences, Department of Infection, Immunity and Cardiovascular Disease, POLARIS, University of Sheffield, Sheffield, UK.
Jonathan GoldinMedQIA, Los Angeles, CA, USA.
Matthew S BrownMedQIA, Los Angeles, CA, USA.
Konstantinos KostikasUniversity of Ioannina Medical School, Ioannina, Greece.
Kristin BelmoreNovartis Institutes for Biomedical Research, Cambridge, MA, USA.
Robert FogelNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Francesco PatalanoNovartis Pharma AG, Basel, Switzerland.
Anton DrollmannNovartis Pharma AG, Basel, Switzerland.
Surendra MachineniNovartis Healthcare Pvt, Ltd, Hyderabad, India.
Ieuan JonesNovartis Pharma AG, Basel, Switzerland.
Denise YatesNovartis Institutes for Biomedical Research, Cambridge, MA, USA.
Hanns-Christian TillmannNovartis Institutes for Biomedical Research, Fabrikstrasse 2, Novartis Campus, 4056, Basel, Switzerland. hanns-christian.tillmann@novartis.com.
Novartis (Switzerland) · CHNovartis (United States) · USReva Medical (United States) · USUniversity of Sheffield · GBBradford Teaching Hospitals NHS Foundation Trust · GBNational Institute for Health Research · GBNovartis (India) · INUniversity of Ioannina · GRUniversity of Manchester · GB

Funding

British Heart Foundation SP/14/6/31350Medical Research Council MR/M008894/1
6 · The paper itself

Abstract

rationaleThe long-acting β

objectivesThe primary objective was assessment of effect of IND/GLY on global ventilated lung volume (%VV) versus placebo in COPD. Lung function, regional ventilation and perfusion in response to IND/GLY were also measured.

methodsThis double-blind, randomized, placebo-controlled, crossover study assessed %VV and pulmonary perfusion in patients with moderate-to-severe COPD after 8 days of once-daily IND/GLY treatment (110/50 µg) followed by 8 days of placebo, or vice versa, using inhaled hyperpolarized MEASUREMENTS AND MAIN

resultsOf 31 patients randomized, 29 completed both treatment periods. IND/GLY increased global %VV versus placebo (61.73% vs. 56.73%, respectively, least squares means treatment difference: 5.00% [90% CI 1.40 to 8.60]; P = 0.025). IND/GLY improved whole lung index of ventilation volume to perfusion volume (V/Q) ratio versus placebo; 94% (90% CI 83 to 105) versus 86% (90% CI 75 to 97; P = 0.047), respectively. IND/GLY showed a trend to improve diffusing capacity for carbon monoxide (DL

conclusionsIND/GLY improved lung ventilation assessed by

Indexed as

AgedBronchoconstrictionCross-Over StudiesDouble-Blind MethodDrug CombinationsFemaleFollow-Up StudiesForced Expiratory VolumeGlycopyrrolateHumansIndansLungMaleMiddle AgedPulmonary Disease, Chronic ObstructiveQuinolonesDrug CombinationsGlycopyrrolateindacaterol-glycopyrronium combinationIndansQuinolonesChronic obstructive pulmonary diseaseHyperpolarized 3He gas magnetic resonance imagingIndacaterol/glycopyrroniumVentilation/perfusion ratioVentilation volume and perfusion volumeV/Q index

Identifiers

PMID35144620
PMCPMC8832861
OpenAlexW4211115343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.